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Background: Experimental studies have shown that doxycycline (DOX) attenuates post-myocardial infarction (MI) remodeling through matrix 
metalloproteinase inhibition, and exerts protective effects on myocardial ischemia/reperfusion injury. We assessed the effect of DOX on left ventricular 
(LV) remodeling in patients with acute ST-elevation MI (STEMI) and moderate LV dysfunction treated with primary coronary intervention (PCI).
Methods: Single-blinded, randomized, phase III trial (ClinicalTrial.gov Identifier: NCT00469261). Patients with acute STEMI and LV ejection fraction 
< 40 % successfully treated with primary PCI and stenting, were randomly assigned to oral DOX (100 mg at admission and then 100 mg b.i.d. for 7 
days) in addition to standard therapy [DOX group] or to standard care [control group]. Echo LV end-diastolic and end-systolic volumes index (EDVi 
and ESVi) were determined at baseline, pre-discharge, 1 and 6 months. 99mTc Sestamibi SPECT infarct size/severity, and coronary infarct-related 
artery (IRA) patency were assessed at 6 months. The primary end-point was echo Δ % LVEDVi (baseline to 6 months). Based on experimental results, 
we calculated a sample size of 110 patients (55 per group), assuming that DOX would reduce Δ % LVEDVi > 50% as compared to standard therapy, 
considering an attrition rate of 15%, and a statistical power of 90% with a type I error _ = .05. The secondary end-point was scintigraphic infarct 
size/severity.
Results: Out 110 patients enrolled, 97 (88%) completed 6-month echo follow-up (DOX group 51 patients, control group 46 patients). The 2 groups 
were well balanced on baseline clinical and procedural characteristics. IRA patency rate at follow-up was 99% in the entire patient cohort. At 6 
month Δ % LVEDVi was signficantly lower in DOX group than in control group: - 5 ± 27% vs + 25 ± 41%, respectively (p < .001). Infarct size and 
severity were inferior in DOX group than in control group: 10 ± 12% vs 16 ± 15%, p = .04, and 0.5 ± 0.1 vs 0.4 ± 0.2, p = .01, respectively.
Conclusions: In patients with acute STEMI and LV dysfunction, early short-term DOX therapy was associated with a lower LV remodeling and 
smaller infarct size/severity, as compared to standard therapy.
